VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization
Author:
Affiliation:
1. State Key Laboratory of Cancer Biology, Department of Immunology, Air Force Medical University, Xi'an, Shaanxi 710032, P.R. China
2. Department of Urology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710069, P.R. China
Publisher
Spandidos Publications
Subject
Cancer Research,Oncology
Reference58 articles.
1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022
2. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants;Xia;Chin Med J (Engl),2022
3. Hormonal therapy for prostate cancer;Desai;Endocr Rev,2021
4. Treatment of advanced prostate cancer;Teo;Annu Rev Med,2019
5. Ras and Wnt interaction contribute in prostate cancer bone metastasis;Lin;Molecules,2020
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The m6A regulators in prostate cancer: molecular basis and clinical perspective;Frontiers in Pharmacology;2024-08-29
2. lncRNAs: New players of cancer drug resistance via targeting ABC transporters;IUBMB Life;2024-08
3. Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms;Heliyon;2024-03
4. Single-cell profiling and functional screening reveal crucial roles for lncRNAs in the epidermal re-epithelialization of human acute wounds;Frontiers in Surgery;2024-02-26
5. lncRNA VIM-AS1 acts as a prognostic biomarker and promotes apoptosis in lung adenocarcinoma;Journal of Cancer;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3